Literature DB >> 16621717

Gene-based vaccines: recent technical and clinical advances.

Jeffrey B Ulmer1, Britta Wahren, Margaret A Liu.   

Abstract

DNA vaccines have been widely used in efforts to develop vaccines against various pathogens as well as for cancer, autoimmune diseases and allergy. DNA vaccines offer broad efficacy (particularly for their ability to generate both cellular and humoral immunity), ease of construction and manufacture and the potential for world-wide usage even in low-resource settings. However, despite their successful application in many preclinical disease models, their potency in human clinical trials has been insufficient to provide protective immunity. Nevertheless, two DNA vaccines were recently licensed for use in animals (horse and fish), underscoring the potential of this technology. Here, we describe recent advances in increasing the potency of these vaccines, in understanding their immunological mechanisms, and in their applications and efficacy in clinical trials so far.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621717     DOI: 10.1016/j.molmed.2006.03.007

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  56 in total

Review 1.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

Review 2.  Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.

Authors:  Shaw-Wei D Tsen; Augustine H Paik; Chien-Fu Hung; T-C Wu
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

3.  Immunodominant peptides from conserved influenza proteins--a tool for more efficient vaccination in the elderly?

Authors:  Giovanni Almanzar; Dietmar Herndler-Brandstetter; Sandra Vega Chaparro; Brigitte Jenewein; Michael Keller; Beatrix Grubeck-Loebenstein
Journal:  Wien Med Wochenschr       Date:  2007

4.  The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells.

Authors:  Godwin Nchinda; Janelle Kuroiwa; Margarita Oks; Christine Trumpfheller; Chae Gyu Park; Yaoxing Huang; Drew Hannaman; Sarah J Schlesinger; Olga Mizenina; Michel C Nussenzweig; Klaus Uberla; Ralph M Steinman
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

5.  Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers.

Authors:  Malissa C Diehl; Jessica C Lee; Stephen E Daniels; Pablo Tebas; Amir S Khan; Mary Giffear; Niranjan Y Sardesai; Mark L Bagarazzi
Journal:  Hum Vaccin Immunother       Date:  2013-06-04       Impact factor: 3.452

6.  Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Authors:  Charles H Jones; Anders P Hakansson; Blaine A Pfeifer
Journal:  J Mater Chem B       Date:  2014-09-12       Impact factor: 6.331

7.  IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine.

Authors:  Sandra A Calarota; Anlan Dai; Jeffrey N Trocio; David B Weiner; Franco Lori; Julianna Lisziewicz
Journal:  Vaccine       Date:  2008-04-14       Impact factor: 3.641

8.  A TaqMan reverse transcription polymerase chain reaction (RT-PCR) in vitro potency assay for plasmid-based vaccine products.

Authors:  Rohit Mahajan; Beth Feher; Basil Jones; Doug Jones; Lana Marjerison; Mindy Sam; Jukka Hartikka; Mary Wloch; Peggy Lalor; David Kaslow; Keith Hall; Alain Rolland
Journal:  Mol Biotechnol       Date:  2008-03-26       Impact factor: 2.695

9.  Uptake and presentation of exogenous antigen and presentation of endogenously produced antigen by skin dendritic cells represent equivalent pathways for the priming of cellular immune responses following biolistic DNA immunization.

Authors:  Stephan Sudowe; Sabine Dominitzki; Evelyn Montermann; Matthias Bros; Stephan Grabbe; Angelika B Reske-Kunz
Journal:  Immunology       Date:  2008-09-17       Impact factor: 7.397

Review 10.  Current status of vaccines for schistosomiasis.

Authors:  Donald P McManus; Alex Loukas
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.